Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.53 |
| ▸ | RXRA | P19793 | 7/20 | 0.50 |
| ▸ | RXRB | P28702 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 2/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27698928 | 0.93 | PLA2G4B (0.53) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL27754204 | 0.85 | RARB (0.47) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL27613996 | 0.84 | NR4A2 (0.59) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL1750568 | 0.83 | PLA2G4B (0.63) | ALDH1A1RXRARXRBPLA2G4BNPC1 | |
| SCHEMBL25960462 | 0.83 | ALDH1A1 (0.54) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL27595132 | 0.83 | ALDH1A1 (0.54) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL27719363 | 0.83 | ALDH1A1 (0.54) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL27698909 | 0.83 | ALDH1A1 (0.58) | ALDH1A1NR4A2RXRARXRBHPGD | |
| SCHEMBL1749669 | 0.81 | PLA2G4B (0.65) | ALDH1A1PLA2G4B | |
| SCHEMBL28317367 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NR4A2RXRARXRBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371808-A1 | Process for preparing dronedarone | Ratiopharm GmbH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ALDH1A1 4542/4885NR4A2 532/4885RXRA 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.